Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2024 Financial Results on November 12, 2024
16 oct. 2024 07h30 HE
|
Organogenesis Holdings Inc.
CANTON, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Organogenesis Announces Publication of Randomized Clinical Trial Results Demonstrating the Safety and Efficacy of NuShield for Diabetic Foot Ulcers
01 oct. 2024 16h05 HE
|
Organogenesis Holdings Inc.
Robust 218-patient RCT demonstrates statistically superior frequency of wound closure at 12 weeks compared to standard of care (p=.04) Organogenesis believes published study satisfies requirements...
Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in September
04 sept. 2024 16h05 HE
|
Organogenesis Holdings Inc.
CANTON, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization...
Organogenesis Holdings Inc. Reports Second Quarter 2024 Financial Results
08 août 2024 16h05 HE
|
Organogenesis Holdings Inc.
CANTON, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Organogenesis Shares ReNu® Program Update
08 août 2024 16h04 HE
|
Organogenesis Holdings Inc.
On track to submit ReNu BLA by the end of 2025Enrollment in second Phase 3 complete; significantly ahead of expectationsSubgroup analysis demonstrated most severe (KL4) subjects responded comparably...
Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2024 Financial Results on August 8, 2024
15 juil. 2024 16h05 HE
|
Organogenesis Holdings Inc.
CANTON, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization...
Organogenesis Holdings Inc. to Participate in the Truist Securities MedTech Conference
06 juin 2024 16h05 HE
|
Organogenesis Holdings Inc.
CANTON, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Organogenesis Holdings Inc. Reports First Quarter 2024 Financial Results
09 mai 2024 16h05 HE
|
Organogenesis Holdings Inc.
CANTON, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu® for Knee Osteoarthritis
02 mai 2024 07h00 HE
|
Organogenesis Holdings Inc.
Statistically significant (p=0.0177) reduction in knee pain at six monthsStatistically significant (p<0.0001) maintenance of function at six monthsTransformational opportunity for Organogenesis to...
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024
16 avr. 2024 07h30 HE
|
Organogenesis Holdings Inc.
CANTON, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization...